Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Registered for use in people aged ≥2 months.
MenACWY-CRM — quadrivalent meningococcal (serogroups A, C, W, Y)–CRM197 conjugate vaccine
Lyophilised powder containing serogroup A in a monodose vial with a pre-filled syringe or vial containing serogroups C, W and Y in saline suspension.
Each 0.5 mL reconstituted dose contains:
- 10 µg meningococcal polysaccharide serogroup A conjugated to 16.7–33.3 µg Corynebacterium diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup C conjugated to 7.1–12.5 µg C. diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup W conjugated to 3.3–8.3 µg C. diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup Y conjugated to 5.6–10 µg C. diphtheriae CRM197 protein
Also contains traces of:
- sucrose
- natural rubber
For Product Information and Consumer Medicine Information about Menveo visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.